Last updated on July 2019

Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma


Brief description of study

A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma

Detailed Study Description

This is a multicentre, randomized, double-blind, placebo controlled, parallel group study designed to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma on medium to high-dose ICS and at least one additional asthma controller medication with or without OCS. Approximately 1060 subjects will be randomized globally. Subjects will receive tezepelumab, or placebo, administered via subcutaneous injection at the study site, over a 52-week treatment period. The study also includes a post-treatment follow-up period of 12 weeks.

Clinical Study Identifier: NCT03347279

Find a site near you

Start Over

Research Site

Bunkyo-ku, Japan
0.7miles
  Connect »

Research Site

Shinjuku-ku, Japan
2.09miles
  Connect »

Research Site

Chuo-ku, Japan
2.23miles
  Connect »

Research Site

Toshima-ku, Japan
2.23miles
  Connect »

Research Site

Sumida-ku, Japan
2.47miles
  Connect »

Research Site

Minato-ku, Japan
3.0miles
  Connect »

Research Site

Itabashi-ku, Japan
4.47miles
  Connect »

Research Site

Shibuya-ku, Japan
4.75miles
  Connect »

Research Site

Edogawa-ku, Japan
7.28miles
  Connect »

Research Site

Shinagawa-ku, Japan
7.41miles
  Connect »

Research Site

Ohota-ku, Japan
8.01miles
  Connect »

Research Site

Setagaya-ku, Japan
8.53miles
  Connect »